26-Dec-2025
Guardant Health is the top performing healthcare services stock YTD
Seeking Alpha News (Mon, 22-Dec 2:03 PM ET)
Hims & Hers Brings Comprehensive Weight Loss Programme to the UK
Business Wire (Wed, 10-Dec 3:30 AM ET)
From Hype to P&L: Hospitals Now Buying AI That Pays
Globe Newswire (Mon, 8-Dec 1:18 PM ET)
Hims & Hers Acquires YourBio Health, Pushing Pain-Free Blood Sampling to the Forefront
Market Chameleon (Thu, 4-Dec 5:36 AM ET)
Market Chameleon (Thu, 4-Dec 2:51 AM ET)
Hims & Hers Continues Major International Expansion With Official Entry Into Canada
Business Wire (Thu, 4-Dec 7:00 AM ET)
Hims & Hers Now Serving Customers in Canada
Business Wire (Thu, 4-Dec 7:00 AM ET)
Hims & Hers to Acquire YourBio Health, Pioneer Behind Advanced, Pain-Free Blood Sampling Technology
Business Wire (Wed, 3-Dec 9:00 AM ET)
Globe Newswire (Tue, 2-Dec 8:00 AM ET)
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization
Business Wire (Mon, 17-Nov 8:00 AM ET)
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Hims & Hers Health Class A trades on the NYSE stock market under the symbol HIMS.
As of December 26, 2025, HIMS stock price declined to $34.31 with 8,874,944 million shares trading.
HIMS has a beta of 1.94, meaning it tends to be more sensitive to market movements. HIMS has a correlation of 0.12 to the broad based SPY ETF.
HIMS has a market cap of $7.81 billion. This is considered a Mid Cap stock.
Last quarter Hims & Hers Health Class A reported $599 million in Revenue and $.09 earnings per share. This beat revenue expectation by $18 million and missed earnings estimates by -$.01.
In the last 3 years, HIMS traded as high as $72.98 and as low as $5.65.
The top ETF exchange traded funds that HIMS belongs to (by Net Assets): VTI, IJH, IWM, VB, VBK.
HIMS has outperformed the market in the last year with a return of +21.9%, while the SPY ETF gained +16.0%. However, in the most recent history, HIMS shares have underperformed the stock market with its stock returning -35.6% in the last 3 month period and -9.4% for the last 2 week period, while SPY has returned +4.7% and +0.7%, respectively.
HIMS support price is $33.57 and resistance is $35.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIMS shares will trade within this expected range on the day.